PCOS Is Now Called PMOS: What the Name Change Means, Why It Happened, and What Changes for You

If you’ve been diagnosed with polycystic ovary syndrome – or if you’ve been searching your symptoms and landing on PCOS as a possibility – there’s something important you need to know. As of May 2026, PCOS has an official new name: Polyendocrine Metabolic Ovarian Syndrome, or PMOS.

This isn’t a rebrand. It’s not a different condition. And it’s not just semantics. The name change reflects a fundamental shift in how the medical community understands what this condition actually is – and it matters for how it gets diagnosed, treated, and talked about.

Where This Change Came From

The renaming wasn’t a decision made overnight. It was the result of a 14-year global consensus process involving more than 56 leading academic, clinical, and patient organizations worldwide – including endocrinology, gynecology, metabolism, and reproductive medicine societies. The process was published in The Lancet in May 2026.

The conclusion: the old name, polycystic ovary syndrome, was doing more harm than good.

Here’s why.

“Polycystic ovary syndrome” implies the defining feature of the condition is cysts on the ovaries. But this is misleading in two important ways. First, many women with the condition don’t have polycystic ovaries at all. Second, the cysts that do appear aren’t actually pathological cysts in the traditional sense – they’re small follicles that haven’t fully developed due to disrupted ovulation. Calling them “cysts” created decades of confusion, unnecessary anxiety, and misdiagnosis.

More importantly, the old name completely missed what the condition actually involves: a complex, multisystem disorder affecting the endocrine system, metabolism, reproductive function, cardiovascular health, and mental health simultaneously. “Polycystic ovary syndrome” made it sound like an ovarian problem. PMOS acknowledges what it actually is – a polyendocrine, metabolic condition that happens to affect the ovaries, among other systems.

The name PCOS was considered “inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing.” Those are the words of the global consensus panel – not a fringe opinion.

What PMOS Actually Is

PMOS is the most common endocrine disorder in women of reproductive age, affecting between 5% and 18% of women globally depending on the diagnostic criteria used. In the United States, that translates to an estimated 5-6 million women – and a significant number remain undiagnosed for years.

It’s a condition defined by hormonal imbalance, specifically the overproduction of androgens (male hormones like testosterone) by the ovaries – and often the adrenal glands too. That hormonal disruption cascades through multiple body systems at once.

The core features:

Hyperandrogenism: Elevated androgens are the defining endocrine feature of PMOS. This produces the visible symptoms most people associate with the condition – excess facial and body hair (hirsutism), acne, and scalp hair thinning. These aren’t cosmetic side effects. They’re direct consequences of androgen excess acting on hormone-sensitive tissue throughout the body.

Menstrual and ovulatory disruption: Excess androgens disrupt the normal hormonal signals that trigger ovulation. Without regular ovulation, periods become irregular, infrequent, or absent entirely. This is also the primary mechanism behind PMOS-related infertility – not an inability to conceive in principle, but unpredictable or absent ovulation making conception difficult to time.

Metabolic dysfunction: Insulin resistance is present in approximately 85% of people with PMOS – including 75% of lean women with the condition. When cells don’t respond properly to insulin, the pancreas compensates by producing more. High insulin levels then amplify androgen production from the ovaries, which worsens the hormonal imbalance. This creates a self-reinforcing cycle that connects the metabolic and endocrine features of PMOS at a biological level.

Ovarian follicle changes: The disrupted ovulation cycle leads to the accumulation of small, immature follicles in the ovaries – visible on ultrasound as what was historically called “cysts.” They’re not cysts in the medical sense (fluid-filled sacs). They’re follicles that started developing but didn’t complete the ovulation process. This distinction matters because many women with PMOS don’t have this finding, and women without PMOS sometimes do.

How PMOS Is Diagnosed

The diagnostic criteria haven’t changed with the name – the Rotterdam criteria, adopted in 2003 and updated since, remain the standard. A diagnosis of PMOS requires at least two of the following three features:

Crucially, PMOS is a diagnosis of exclusion – other conditions that produce similar features must be ruled out first. These include:

• Thyroid disorders (hypothyroidism causes irregular periods and weight changes)
• Hyperprolactinemia (elevated prolactin disrupts ovulation)
• Congenital adrenal hyperplasia (CAH) – particularly non-classical 21-hydroxylase deficiency, which closely mimics PMOS
• Cushing’s syndrome (cortisol excess)
• Androgen-secreting tumors (rare but important to exclude when testosterone is markedly elevated)

Blood tests used in the diagnostic workup typically include: total and free testosterone, LH, FSH, AMH (anti-Müllerian hormone), prolactin, TSH, fasting glucose and insulin, HbA1c, and a lipid panel.

The AMH update: One of the diagnostic advances reflected in recent PMOS guidance is the use of AMH as an alternative to pelvic ultrasound for identifying ovarian follicle changes. AMH levels are consistently elevated in PMOS due to the large number of small follicles, and measuring AMH avoids the need for transvaginal ultrasound – an important consideration for younger adolescents and those who prefer not to have the procedure. Age-specific AMH thresholds are still being refined.

What the New Name Gets Right That the Old One Didn’t

The shift from PCOS to PMOS isn’t just terminological housekeeping. It has concrete clinical implications.

It removes the cyst misconception. For decades, women diagnosed with PCOS were told they had “cysts on their ovaries” – generating anxiety about ovarian damage, cancer risk, and fertility outcomes that wasn’t warranted. The new name eliminates this at the source.

It frames the condition as systemic. PMOS correctly signals that this condition affects multiple endocrine axes simultaneously – ovarian, adrenal, hypothalamic-pituitary, and metabolic. This framing encourages clinicians to screen for and manage the full spectrum of metabolic and cardiovascular risks, not just reproductive symptoms.

It reduces stigma around weight. “Polycystic ovary syndrome” carried an implicit association with a reproductive or gynecological problem. PMOS, by highlighting the metabolic dimension, reframes the weight and metabolic challenges many women experience as features of the underlying condition – not personal failures or lifestyle consequences.

It opens the door to better research. The consensus panel explicitly noted that the old framing was “curtailing research and policy framing.” A name that accurately describes the condition’s biology attracts more targeted research funding and more precise clinical trial design.

The Body-Wide Consequences of PMOS

Understanding PMOS as a polyendocrine metabolic disorder – not a reproductive one – means understanding its consequences beyond the menstrual cycle.

Cardiovascular risk: Women with PMOS have higher rates of hypertension, dyslipidemia (elevated triglycerides, low HDL), and endothelial dysfunction. Studies have found evidence of coronary and aortic calcification at higher rates than in women without the condition. The AHA recognizes PMOS as a cardiovascular risk factor in women.

Type 2 diabetes: The insulin resistance central to PMOS significantly elevates type 2 diabetes risk. Women with PMOS are 2-4 times more likely to develop type 2 diabetes than women without it, and progression from prediabetes to diabetes can occur faster.

Fatty liver disease (MASLD): Obesity, insulin resistance, and androgen excess are all independent risk factors for metabolic-associated steatotic liver disease. PMOS combines all three in a significant proportion of affected women.

Mental health: Depression and anxiety are substantially more prevalent in women with PMOS than in the general female population – driven by a combination of hormonal factors, the visible symptoms of hyperandrogenism (hirsutism, acne, hair loss), fertility concerns, weight challenges, and often years of delayed or dismissed diagnosis.

Sleep disorders: Obstructive sleep apnea is more common in PMOS, even in women without obesity, likely related to androgenic effects on upper airway muscle tone and central respiratory control.

Endometrial cancer: Chronic anovulation means the uterine lining (endometrium) is continuously exposed to estrogen without the opposing effect of progesterone that normally follows ovulation. Over time, this unopposed estrogen exposure increases the risk of endometrial hyperplasia and endometrial cancer. Regular withdrawal bleeds – through progestins or the combined oral contraceptive pill – are used to mitigate this risk in women with infrequent periods.

What Doesn’t Change With the New Name

The condition is the same. The biology is the same. The treatments are the same. What changes is the framing – which shapes everything from how doctors discuss the condition with patients to how research is funded and what the public understands about it.

Treatment still focuses on:

• Lifestyle modification as the foundation – particularly for women with metabolic features. Even modest weight loss (5-10% of body weight) in women with PMOS who are overweight can restore ovulation, improve insulin sensitivity, reduce androgen levels, and improve both metabolic and reproductive outcomes. This isn’t about body weight for its own sake – it’s about the metabolic effects that respond meaningfully to even modest changes.
• Combined oral contraceptive pill (COC) – for menstrual regulation, endometrial protection, and management of hyperandrogenism symptoms (acne, hirsutism) in women not trying to conceive.
• Metformin – for insulin resistance, metabolic management, and as a complement to lifestyle intervention. The ADA and Endocrine Society recognize metformin as a useful tool in PMOS management, particularly for metabolic risk reduction.
• Anti-androgens (spironolactone, finasteride) – for hirsutism and acne in women where these symptoms are the primary concern.
• Ovulation induction (letrozole, clomiphene, gonadotropins) – for women trying to conceive. Letrozole is now the first-line agent for ovulation induction in PMOS, having demonstrated superior live birth rates to clomiphene in the landmark PCOSACT trial.
• GLP-1 receptor agonists – increasingly relevant given the overlap between PMOS and metabolic syndrome. Early data suggests GLP-1 agonists (semaglutide, tirzepatide) may improve insulin resistance, androgen levels, and menstrual regularity in PMOS alongside their weight and metabolic effects.

What This Means If You Have a PCOS Diagnosis

If you were diagnosed with PCOS before May 2026, your diagnosis is still valid and nothing about your care needs to change urgently. PMOS is the same condition with the same diagnostic criteria – you don’t need to be rediagnosed.

What you might want to do:

• Ask your doctor about screening for the metabolic features of PMOS if these haven’t been assessed – fasting glucose or HbA1c, fasting lipid panel, blood pressure, and waist circumference
• Understand that your condition affects more than your reproductive system and warrants ongoing monitoring for cardiovascular and metabolic risk
• If you were told you have “cysts on your ovaries” and have been worried about this – the new framing confirms those aren’t cysts in the pathological sense, and ovarian cancer risk is not elevated in PMOS

Frequently Asked Questions

Do I need to tell my doctor my diagnosis name has changed? Your medical records may still say PCOS for some time – the transition to PMOS in clinical documentation will happen gradually. You don’t need to take any urgent action, but it’s worth mentioning if it comes up in an appointment. The key is that your provider understands you have this condition and is monitoring the full range of its features – not just reproductive symptoms.

Does the name change mean the condition is better understood now? Yes – the renaming reflects real advances in understanding. The 14-year consensus process was driven by research establishing PMOS as a polyendocrine metabolic condition with polygenic origins spanning neuroendocrine, metabolic, and reproductive pathways. The name catches up to the science.

Will insurance coverage change because of the name change? This is evolving. ICD coding will eventually transition to reflect the new name, but this takes time. Currently, the underlying diagnostic codes remain the same. If you encounter insurance issues, your doctor can clarify that PMOS is the renamed form of PCOS with the same clinical criteria.

Does PMOS affect men? PMOS is primarily a condition of people assigned female at birth. However, the consensus panel noted that male relatives of women with PMOS often show metabolic features including insulin resistance, dyslipidemia, and early-onset type 2 diabetes – suggesting shared genetic susceptibility to metabolic dysfunction. Research into the “male phenotype” of PMOS is ongoing.

I was told I don’t have cysts so I don’t have PCOS. Does PMOS change anything for me? Potentially yes. The Rotterdam diagnostic criteria only require two of three features for diagnosis – you don’t need polycystic ovarian morphology on ultrasound. If you have irregular periods and biochemical or clinical evidence of hyperandrogenism, a diagnosis of PMOS can be made without cysts on ultrasound. If you were previously told you don’t have PCOS because your ultrasound was normal but you have other features, it’s worth revisiting with a provider familiar with the updated criteria.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. The diagnostic and treatment information here reflects current clinical guidelines as of June 2026. If you have symptoms consistent with PMOS or have an existing PCOS diagnosis, consult a qualified healthcare provider – ideally one with expertise in endocrinology, gynecology, or reproductive medicine.

References

1. Teede HJ, Norman RJ, Tay CT, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. https://doi.org/10.1016/S0140-6736(26)00717-8
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction. 2004;19(1):41-47. https://doi.org/10.1093/humrep/deh098
3. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016;2:16057. https://doi.org/10.1038/nrdp.2016.57
4. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447-2469. https://doi.org/10.1210/clinem/dgad463
5. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome (PCOSACT). New England Journal of Medicine. 2014;371(2):119-129. https://doi.org/10.1056/NEJMoa1313517
6. National Institute of Child Health and Human Development (NICHD). Polycystic ovary syndrome. https://www.nichd.nih.gov/health/topics/pcos
7. American Heart Association. Polycystic ovary syndrome and heart disease risk. https://www.heart.org
8. Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. The Lancet Diabetes & Endocrinology. 2022;10(9):668-680. https://doi.org/10.1016/S2213-8587(22)00163-2
9. Centers for Disease Control and Prevention (CDC). PCOS (polycystic ovary syndrome) and diabetes. https://www.cdc.gov/diabetes/library/features/pcos.html
10. Cleveland Clinic. Polyendocrine metabolic ovarian syndrome (PMOS). https://my.clevelandclinic.org/health/diseases/8316-polycystic-ovary-syndrome-pcos